FDA investigates deaths of patients on antipsychotic drug

June 19, 2013
FDA investigates deaths of patients on antipsychotic drug
Following the deaths of two patients three to four days after receiving a dose of Zyprexa Relprevv (olanzapine pamoate) via intramuscular injection, the U.S. Food and Drug Administration is conducting an investigation into the possible cause.

(HealthDay)—Following the deaths of two patients three to four days after receiving a dose of Zyprexa Relprevv (olanzapine pamoate) via intramuscular injection, the U.S. Food and Drug Administration is conducting an investigation into the possible cause.

The patients were well outside the three-hour window of monitoring required by the antipsychotic drug's Risk Evaluation and Mitigation Strategy (REMS), but were found to have very high blood levels of after death.

In addition to the three-hour monitoring period, REMS protocol requires patients to receive injections only at REMS-certified facilities and to be accompanied home after the monitoring period. The drug's label warns against possible post-injection delirium sedation syndrome, in which the agent enters the blood too quickly and causes heavy sedation (possibly coma) and/or delirium.

According to the agency, "FDA is providing this information to while it continues its investigation. If therapy with Zyprexa Relprevv is started or continued in patients, health care professionals should follow the REMS requirements and drug label recommendations. Patients and caregivers should talk to their health care professional(s) about any questions or concerns."

Explore further: FDA encourages opioid prescribers to pursue training

More information: More Information

Related Stories

FDA encourages opioid prescribers to pursue training

March 12, 2013

(HealthDay)—Prescribers of extended-release/long-acting (ER/LA) opioid analgesics are encouraged to participate in continuing medical education (CME) provided by manufacturers of these analgesics, according to an open letter ...

FDA reports Samsca may cause liver damage

May 2, 2013

(HealthDay)—After reviewing data from recent large clinical trials, the U.S. Food and Drug Administration has determined that Samsca (tolvaptan) should not be used for longer than 30 days and should not be used at all by ...

FDA to decide on Qnexa obesity drug in July

April 10, 2012

US regulators will decide in July whether to approve Qnexa, the first obesity drug in more than a decade, extending the initial deadline by three months, the California-based drug-maker VIVUS said.

FDA: Omontys injection pulled from market

February 26, 2013

(HealthDay)—Affymax Inc. of Palo Alto, Calif., and Takeda Pharmaceuticals Company Limited of Deerfield, Ill., have voluntarily recalled all lots of Omontys Injection, used to treat anemia in adult dialysis patients, following ...

Antipsychotics accelerate patient sedation, study finds

October 9, 2012

(Medical Xpress)—A new study is shedding light on the use of sedative drugs in hospitals and has proven certain clinically used drug combinations to be faster and more effective in sedating highly aggressive patients in ...

Recommended for you

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.